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Summary. Oral vitamin KI is used for the treatment of
excessive anticoagulation. Detailed Information on changes
in the International Normalized Ratio (INR) in response to
vitamin K! is not available. We therefore measured the INR
for the flrst 7 d following the oral intake of l - 5 mg of vitamin
K! in 24 patients routinely treated with phenprocoumon
who had an INR &6-0 at Präsentation. On the flrst 2 d after
administration of vitamin KI, the mean INR decreased by
40% and 23% respectively. After day 2, the day-to-day
proportional change in the mean INR depended on the dose
of vitamin KI and varied from a decrease of 12% to an
increase of 21%. On day 7 the mean INR was higher than on
day 2 in three out of flve treatment groups. Between day 2
and day 7, in general, 32% of the patients had an INR value
within the target zone, 25% had an INR value 3=6-0 and 8%
had an INR value <2·0. These Undings suggest that our
routine treatment of overanticoagulation in patients on
phenprocoumon should be intensified to improve its efflcacy.
Keywords: overanticoagulation, coumarin anticoagulants,
vitamin KI, International Normalized Ratio, efficacy.
Oral anticoagulants have a narrow therapeutic index
(Rosendaal, 1996). The optimal therapeutic ränge of oral
anticoagulant therapy, äs recommended by the Federation of
Dutch Thrombosis Centres, lies between 2-5 and 3-5
International Normalized Ratio (INR) or between 3-0 and
4-0 INR (Cannegieter et a/, 1995; The SPIRIT Study Group,
1997), depending on the indication for treatment. When the
INR is >6O the risk of bleeding, the most common adverse
reaction to oral anticoagulants, sharply increases (Canne-
gieter ei al, 1995). Therefore such an excess anticoagulant
effect should be treated promptly and adequately.
In the absence of life-threatening haemorrhagic
complications, the usual way to achieve a reduction in
anticoagulant effect is to discontinue the drug for 2 or more
days and, depending on the intensity of the INR value,
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administer 1-10 mg of vitamin K! orally (Federatie van
Nederlandse Trombosediensten, 1987). Detailed information
on changes in the International Normalized Ratio in
response to vitamin K! is not available since INR values
are usually not measured daily, but only after a week. The
literature provides limited information: two studies have
been performed on the response of the INR to oral vitamin KI
(Weibert et al, 1997; Pengo et al, 1993). In one (Weibert et al,
1997) the INR was measured twice: l or 2d after
administration of vitamin Kj and 4-7 d after warfarin
therapy was resumed. In the other study (Pengo et αϊ, 1993)
the INR value was determined after l, 2 and 9d. These
studies both focused on efficacy and expressed the results in
the number of patients with an INR below or above 5-0. No
data were given on changes in INR over time. Harrell & Kline
(1995) reported on five patients in whom oral vitamin K!
was used to treat overanticoagulation. After l or 2 d the INR
had decreased by 58% to 89%.
To obtain detailed insight into the course of the INR after
oral administration of vitamin KI and to test the efficacy of
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our routine treatment of overanticoagulation, we deter-
mined the INR value over 7 consecutive days in patients on
phenprocoumon who had an INR >6·0 at presentation.
SUBJECTS AND METHODS
Patients treated with phenprocoumon (Marcoumar®) by the
regional Red Cross anticoagulant clinic The Hague who were
prescribed oral Vitamin Kj because of an INR value 5= 6-0
between 9 June 1997 and 27 June 1997, were asked to
participate in this prospective study. Patients treated with
vitamin KI because of a subsequent medical Intervention or
whose prothrombin time had to be checked within 7 d were
excluded.
On day 0 patients suspended phenprocoumon therapy and
took an oral dose of vitamin KI (Konaldon® Cremophor EL-
based drop solution 20 mg/ml). This dose was determined by
the INR value and the target zone of anticoagulation,
according to an algorithm employed at the anticoagulant
clinic (Table I). Because of individual factors, the algorithm
could be deviated from. The required number of drops were
taken with about half a cup of water. The day at which the
patient restarted phenprocoumon, äs well äs the adjustment
of the dosage, depended on the patient's individual
circumstances: Standard practice was to restart phenpro-
coumon on day 2 and to lower the dosage by about 15%.
Table I. Algorithm for the admimstration of vitamin
Kj in patients on phenprocoumon.
was -0-1, 95% CI [-0-5; 0-3], indicating that freezing did
not affect prothrombin time measurement.
To control for other factors that may affect the INR,
patients were asked about their health and changes in co-
medication and alcohol intake during the study period. In
addition, the intake of vitamin KI and phenprocoumon were
verified by questionnaire.
The course of the INR is described in terms of the
proportional change in the mean INR between 2 consecutive
days. Baseline INR and dose of vitamin Kj are highly
correlated: more vitamin KI is prescribed when the INR is
higher (Table I). Therefore we also analysed patients
separately according to the dose of vitamin KI (l, 2, 3, 4
or 5 mg), starting from the patients being compliant. To test
the efficacy of the routine treatment of overanticoagulation,
the frequency of INR values ϊ*6·0, INR values within ihe
target zone (2-0-3-5 INR or 2-5-4-0 INR) and INR values
<2·0 was calculated.
RESULTS
The number of patients treated with vitamin KI and fulfilling
the inclusion criteria in the 3-week study period was 41. Of
the 34 patients we were able to contact, 24 (71%) were
willing to participate, 10 men and 14 women. One patient
was lost to follow-up after day 2. The mean age of the patients
was 70 years (ränge 42-87 years). They had been using
phenprocoumon for 3 d to 19 years, with a median duration
of use of 2 years and 4 months. Indications for anticoagulant
Target zone of anticoagulation













On the next 7 d after taking vitamin K l t day l to day 7,
venous blood samples were collected in 3-2% sodium citrate
Vacutainer tubes. The patients were visited at home between
8.00 and 12.30 a.m. Within 5 h after collection the blood
samples were centrifuged at 3000rpm for 10 min and
plasma was frozen at —20°C. Prothrombin times were
measured after the 1-week follow-up in order not to affect
treatment. All measurements were done at the same time on
an automatic coagulation analyser (Electra 1500C). The
thromboplastin used was a human recombinant tissue factor
(Ortho® RecombiPlasTin) with an international sensitivity
index of 1-05 (batch RTF-159).
To confirm the assumption of no effect of freezing on the
prothrombin time measurement, two blood samples were
taken on day 7. Of one of these samples plasma was frozen
and the prothrombin time was measured afterwards. Of the
other sample the prothrombin time was measured directly.
The mean difference in the INR value between both samples
0 1 2 3 4 5 6 7
days after administration of vitamin K1
Fig 1. Course of the INR (mean ± SE) during the first week after
administration of vitamin KI m patients overanticoagulated with
phenprocoumon. The grey area indicates the target zone.
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therapy were: cardiac disease (13 patients), cerebrovascular
thromboembolism (four patients), peripheral arterial disease
(three patients), venous embolism (two patients) and
prophylactic venous treatment (two patients). The INR at
presentation ranged from 7-3 to 14-2, with a mean of 9-3.
The mean dose of vitamin KI prescribed was 2·7mg (ränge
l-5 mg). In 17/24 patients the dose of vitamin KI was
according to the algorithm; seven patients were prescribed a
higher dose.
Fig l shows the course of the INR (mean ± SE) during the
flrst week following administration of vitamin Kj for all
patients combined. On the first 2 d after administration of
vitamin KI, the INR decreased. On day 0, the mean INR was
9-3 ±0-3. On day l and day 2, the mean values were
5-6 ±0-5 and 4·3 ±0-4 respectively. The proportional
decrease in the mean INR was 40% on day l and 23% on
day 2. After day 2, the mean INR did not decrease further,
but slightly increased instead. The day-to-day proportional
increase ranged from 2% to 8%. On day 7, the mean INR was
5-5 ±0-8, 28% higher than the mean value on day 2.
Remarkably, the mean INR did not reach the target zone on
any of the 7 d.
The pattern of a decrease in the INR during the first 2 d
following the intake of vitamin Kj, was observed for all doses
of vitamin KI (Fig 2, upper panel) and for each of the patients
(Fig 2, bottom panel). The extent of the response to oral
vitamin K! varied greatly between patients: the ränge in INR
values on day 0 was much smaller compared to the ränge on
day l and day 2. In a few patients the INR did not decrease
immediately but only after l d.
The course of the INR after day 2 was not consistent. The
day-to-day proportional change in the mean INR depended
on the dose of vitamin KI and varied from a decrease of 12%
to an increase of 21%. On day 7, the mean INR was lower
than on day 2 in the l mg and the 5 mg group and was
higher than on day 2 in the 2, 3 and 4 mg group.
In addition to determining the effect of vitamin KI
administration on the time-course of the INR, we also
looked at its effectiveness in reducing the excess anti-
coagulant effect to lower and safer levels, preferably in the
target zone. Of 24 patients with an INR 5=6-0 on day 0 who
received 1-5 mg of vitamin KI, eight (33%) still had an INR
5=6-0 on day l, five (21%) on day 2, 3 and 4, seven (29%) on
day 5 and day 6 and six (25%) on day 7. This concerned 12
individual patients, five of whom had an INR 5=6-0 on at
least 5 d. All patients had taken <5 mg of vitamin Κχ.
The number of patients with an INR value within the
target zone was five (21%) on day l, eight (33%) on day 2
and day 6, seven (29%) on day 3, day 4 and day 7, and nine
(38%) on day 5. 12 different patients were involved; in three
of them the INR was in the target zone for only l or 2 d.
An INR value <2-0 occurred in two patients (8%) on day
2, 3 and 4.
DISCUSSION
To obtain detailed insight into the course of the INR after oral
administration of vitamin KI in doses of 1-5 mg, we
measured the INR value for 7 consecutive days in patienls
on phenprocoumon with an INR 5=6-0 at presentation. The
first 2 d after administration of vitamin Kj the mean INR
decreased; afterwards it slightly increased again. On all days
the mean INR was above the target zone. After a week 2 5% of
the patients were still overanticoagulated (INR 3=6-0), only
29% had an INR within the target zone and none were
underanticoagulated.
The routine treatment of overanticoagulation employed at
the anticoagulant clinic has not been tested extensively
before and is an empirical one. Therefore one aim of this
study was to test its efficacy. Starting from a duration of effect
of oral vitamin KI of 2 d, äs discussed below, the efficacy of
the treatment can be judged on the INR value between day 2
and day 7. Overall, just 32% of the patients had an INR value
within the target zone, 25% had an INR value 5=6-0 and
consequently were at increased risk of bleeding. An INR
value <2-0, and so an increased risk of thromboembolism,
only occurred on day 2, 3 and 4 in two patients (8%). These
figures indicate that the treatment is not sufficiently intense
and an adjustment is recommended. Increasing the dosage
of vitamin Kj is one possibility. Another Option would be to
administer an additional small dose of vitamin KI on day l
or day 2.
Although this study was only performed at the anti-
coagulant clinic of The Hague, the conclusion regarding the
efficacy of the treatment of overanticoagulation in patients
on phenprocoumon may also apply to many of the other
anticoagulant clinics. Most clinics prescribe comparable
doses of vitamin KI, and some even lower doses.
This study was performed in a setting of routine medical
care. As a consequence, in six patients, three of whom had
just started oral anticoagulant therapy, the Standard practice
ofrestarting phenprocoumon on day 2 and loweringthe dos-
age by about 15% was deviated from. However, the course of
the INR in these patients was comparable with that observed
in the patients in whom the Standard practice was applied.
The greatest effect of vitamin K! was Seen in the first 2 d.
Considering the half-life of vitamin Ka of approximately l · 5 -
3h (Park et al, 1984a, b), a duration of effect of 2 d is
plausible.
The extent of the response to oral vitamin Kj varied
greatly between patients. A difference in the degree of
overanticoagulation is a plausible explanation. However,
serum levels of phenprocoumon were not determined. The
difference between the dose of phenprocoumon at presenta-
tion and the dose in a stable condition at a later time, äs a
proxy of the degree of overanticoagulation, was available for
only a limited number of patients. We did not find a
relationship between the dose of vitamin KI and the
proportional decrease in INR between day 0 and day 2.
Sex and age also were not related to this decrease.
Other factors that may affect the INR were not substan-
tially present and cannot have had an appreciable effect on
the results.
Our study was restricted to patients on phenprocoumon,
since at the anticoagulant clinic of The Hague vitamin KI is
only incidentally prescribed to patients on acenocoumarol,
namely when the INR is >15-0. Because of a difference in
half-life between oral anticoagulants, the course of the INR
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in lesponse to oral Vitamin KI would be düferent lor other
anticoagulants This cispect should be taken into account
when comparmg our study with those öl Weibert et al
(1997) Pengottfl /(1993)andHaireIl&Kline(1995)which
were performed in patients on warfann The foimer two
studies both focused on efflcacy and gave no data on changes
in INR over time In the study of Pengo et al (199 3) nearly all
patients had an INR <5 0 on days l 2 and 9 The INR at
presentation however was much lower than in our studv
Weibert et al (1997) found thdt l or 2 d alter admimstraüon
of vitamm K, 73% of the INR values teil within the target
zone 10% exceeded 5 0 and 17% was <2 0 4-7 d after
warfann therapy was resumed these percentages were 83%
1% and 16% respectively So tompared to our studv tewer
patients had an INR above the target zone but more patients
had an INR below this zone A higher dosage of vitamm KI
m Proportion to the INR at presentation by Weibert et al
(1997) is a plausible explanation
In a report on Rve patients by Harreil & Kirne (1995) the
INR had decreased by 58% to 89% after l or 2 d In our
study the maximum decrease in INR on an mdividual patient
level was 77% on day l and 43% on day 2
In conclusion in this study among 24 patients on
phenprocoumon with an INR ^60 the INR decreased
dunng the first 2 d after adrmnistration ot 1-5 mg ot
oral Vitamin Κχ but slightlv increased agam atterwards
Only one thud öl the patients had an INR value within the
target zone between day 2 and day 7 To improve its efficacy
the routine treatmenl oi overantitoagulalion in patients on
phenproLOumon should be intensihed
INR m Response to Vitamm K, 245
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